SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Recruiting · NCT07131319 · Registry updated 2026-06-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-06-25 | NCT07131319 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Second Affiliated Hospital of Nanchang University | 90 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nanchang City, Jiangxi Province | Nanchang | China | 1 |